Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of RVX000222 for prevention of major cardiovascular events in high-risk adults with type 2 diabetes mellitus and coronary artery disease
2015-002040-14Phase 3Completed
- Sponsor
- Resverlogix Corp.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, coronary arteriosclerosis and type 2 diabetes mellitus (T2DM) comparing RVX000222 with Placebo (2 arms). Started Aug 2015; status: completed.
02
Drugs
apabetalone
03
Conditions
atherosclerotic diseasecoronary arteriosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002040-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002040-14.